
浏览全部资源
扫码关注微信
纸质出版日期:2018
移动端阅览
柏茂树, 王熙才, 孙娇, 等. 参附注射液联合痰热清注射液对老年晚期肺癌脾虚痰湿证化疗的减毒增效作用[J]. 中国实验方剂学杂志, 2018,24(14):159-163.
BAI Mao-shu, WANG Xi-cai, SUN Jiao, et al. Toxicity Reducing and Efficacy Enhancing Effect of Shengfu Injection Combined with Tanreqing Injection on Chemotherapy of Advanced Lung Cancer with Spleen Deficiency and Phlegm Dampness Syndrome in Elderly Patients[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(14): 159-163.
柏茂树, 王熙才, 孙娇, 等. 参附注射液联合痰热清注射液对老年晚期肺癌脾虚痰湿证化疗的减毒增效作用[J]. 中国实验方剂学杂志, 2018,24(14):159-163. DOI: 10.13422/j.cnki.syfjx.20181319.
BAI Mao-shu, WANG Xi-cai, SUN Jiao, et al. Toxicity Reducing and Efficacy Enhancing Effect of Shengfu Injection Combined with Tanreqing Injection on Chemotherapy of Advanced Lung Cancer with Spleen Deficiency and Phlegm Dampness Syndrome in Elderly Patients[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(14): 159-163. DOI: 10.13422/j.cnki.syfjx.20181319.
目的:研究参附注射液联合痰热清注射液益气温阳、化痰解毒改善老年Ⅳ期表皮生长因子受体(EGFR)野生型非小细胞肺癌患者经多西他赛化疗后的减毒增效作用。方法:符合条件的64例患者分为对照组(采用多西他赛单药化疗方案)和治疗组(在对照组基础上加用益气温阳化痰解毒的中医方案),各32例。两组患者均在每周期d1静脉滴注多西他赛注射液75 mg·m-2,治疗组在此基础上,加用中医方案(益气温阳、化痰解毒),即参附注射液60~80 mL加入5%葡糖糖注射液250 mL中静脉滴注,1次/d(qd),痰热清注射液20~30 mL加入5%葡糖糖注射液250 mL中静脉滴注,qd,治疗10 d。每21 d为1个周期,治疗2周期后分别对两组患者进行中医证候,免疫功能,Ⅲ~Ⅳ度骨髓抑制及安全性评价。结果:治疗后,治疗组乏力少气、咯血、咳嗽、咳痰、胸痛、胸闷等中医证候改善情况优于对照组(P < 0.05)。治疗组治疗后外周血CD3+,CD4+,白细胞介素(IL)-27高于对照组(P < 0.05),CD8+,细胞毒性T淋巴细胞相关抗原-4(sCTLA-4)水平低于对照组(P < 0.05)。与对照组治疗后相比,治疗组的Ⅲ/Ⅳ度血液学毒性降低(P < 0.05)。结论:益气温阳、化痰解毒的参附注射液联合痰热清注射液能改善晚期老年非小细胞肺癌的中医证候,增加化疗后患者的免疫功能,减轻血液学毒性,安全性高,具有减毒增效的作用,值得临床推广应用。
Objective: To study the toxicity reducing and efficacy enhancing effect of Shengfu injection combined with Tanreqing injection on chemotherapy by supplementing Qi
warming Yang
resolving phlegm and detoxicating in elderly patients with advanced stage non-small cell lung cancer (NSCLC) of the wild type epithelial growth factor receptor(EGFR)after docetaxel chemotherapy. Method: The 64 eligible patients were divided into 2 groups equally:control group (docetaxel single drug chemotherapy regimen) and treatment group (Chinese medicine regimen with supplementing Qi
warming Yang
resolving phlegm and detoxicating effect based on the treatment in control group). All patients were injected with Docetaxel of 75 mg·m-2 by drip of each cycle in first day
and the patients in treatment group additionally received traditional Chinese medicine (TCM) regimen of Supplementing Qi
warming Yang
and detoxification effect (60-80 mL Shengfu injection was added to 250 mL 5% glucose injection for intravenous drip
qd
and 20-30 mL Tanreqing injection was added to 250 mL 5% glucose injection 250 mL
qd). The TCM regimen was given for 10 days. 21 days were regarded as 1 cycle
and the symptoms of Chinese medicine
immunologic function
Ⅲ-Ⅳ bone marrow suppression and safety were evaluated after 2 cycles' treatment. Result: The improvement of TCM symptoms (weak breath
hemoptysis
cough
expectorating phlegm
chest pain
chest tightness
et al) in the treatment group was better than that in control group
and the difference was statistically significant (P<0.05). After treatment
the peripheral blood CD3+
CD4+ and interleukin (IL)-27 of the treatment group were higher than those of control group (P<0.05)
and CD8+ and cytotoxic T lymphocyte associated antigen-4 (sCTLA-4) were lower than those of the control group (P<0.05)
with statistically significant difference (P<0.05). As compared with control group
the treatment group had a lower hematologic toxicity of grade Ⅲ/Ⅳ (P<0.05). Conclusion: Shengfu injection combined with Tanreqing injection with supplementing Qi
warming Yang
resolving phlegm and detoxicating effect can improve the TCM symptoms of advanced non-small cell lung cancer in elderly patients
increased the immune function of patients after chemotherapy
reduce the toxicity of hematology
with high safety
toxicity reducing and efficacy enhancing effect
so it is worthy of clinical application.
0
浏览量
7
下载量
4
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621